EPRX Eupraxia Pharmaceuticals Inc.
Healthcare$7.53+6.06%ClosedMarket Cap: $252.1M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
3.05
P/S
0.00
EV/EBITDA
-4.26
DCF Value
$1.47
FCF Yield
-12.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-51.1%
ROA
-32.3%
ROIC
-36.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-15.7M | $-12.5M | $— | — |
| Q4 null | $0.00 | NaN% | $-16.2M | $-16.7M | $— | — |
| FY null | $0.00 | -Infinity% | $-53.7M | $-53.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-6.9M | $-6.4M | $— | — |
| Q2 null | $0.00 | NaN% | $-11.3M | $-11.9M | $— | — |
| Q1 null | $0.00 | NaN% | $-10.1M | $-9.6M | $— | — |
| Q4 null | $0.00 | NaN% | $-10.8M | $-10.8M | $— | — |
| FY null | $0.00 | NaN% | $-38.8M | $-36.7M | $— | — |
| Q3 null | $0.00 | NaN% | $-8.5M | $-8.1M | $— | — |
| Q2 null | $0.00 | NaN% | $-9.0M | $-8.2M | $— | — |
| Q1 null | $0.00 | NaN% | $-6.7M | $-6.0M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-12.2M | $-10.2M | $-0.15 | — |